Felodipine
| 證據等級: L5 | 預測適應症: 7 個 |
目錄
- Felodipine
- Felodipine: From Hypertension to Pulmonary Hypertension with Unclear Multifactorial Mechanism
- One-Sentence Summary
- Quick Overview
- Why Is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- All Predicted Indications — Summary
- Best-Evidenced Indication: Prinzmetal Angina (Rank 7)
- Supporting Evidence: Chronic Pulmonary Heart Disease (Rank 6, L4)
- Philippines Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Felodipine: From Hypertension to Pulmonary Hypertension with Unclear Multifactorial Mechanism
One-Sentence Summary
Felodipine is an L-type calcium channel blocker (CCB) used internationally for systemic hypertension, with no current Philippines registration on record. The TxGNN model’s highest-ranked prediction is pulmonary hypertension with unclear multifactorial mechanism (score 99.91%), yet this indication has no supporting clinical trials or directly relevant publications. Critically, among all 7 ranked predictions in this multi-indication analysis, Prinzmetal angina (rank 7) represents a far stronger repurposing opportunity — backed by multiple direct clinical studies of Felodipine and Class I guideline support for CCBs in this condition.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Hypertension (international reference; no Philippines registration on record) |
| Predicted New Indication | Pulmonary hypertension with unclear multifactorial mechanism |
| TxGNN Prediction Score | 99.91% |
| Evidence Level | L5 — model prediction only, no direct studies |
| Philippines Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why Is This Prediction Reasonable?
Detailed mechanism of action data was not available in this evidence pack. Based on established pharmacology, Felodipine is a second-generation dihydropyridine (DHP)-class L-type calcium channel blocker. It selectively inhibits voltage-gated L-type calcium channels in arterial vascular smooth muscle, producing arterial vasodilation, reduced peripheral vascular resistance, and lower systemic blood pressure — with notably high vascular selectivity and minimal cardiac depression compared to non-DHP CCBs such as diltiazem or verapamil.
The TxGNN prediction for pulmonary hypertension is mechanistically grounded at the class level: L-type CCBs can also relax pulmonary arterial smooth muscle and theoretically reduce pulmonary vascular resistance (PVR). In WHO Group 1 pulmonary arterial hypertension (PAH), specific CCBs — nifedipine, amlodipine, and diltiazem — are guideline-endorsed for patients who demonstrate a positive acute vasoreactivity test (AVT+). Felodipine shares this class mechanism and could, in principle, have a comparable hemodynamic effect.
However, the specifically predicted indication — “pulmonary hypertension with unclear multifactorial mechanism” — corresponds to WSPH Group 5 PH, a heterogeneous category encompassing rare systemic conditions (e.g., sarcoidosis, metabolic disorders, haematologic disease). CCBs have no established therapeutic role in Group 5 PH, and Felodipine has no published clinical trial data for any PH subtype. The TxGNN prediction most likely arises from knowledge-graph structural connections (shared cardiovascular phenotype nodes) rather than a direct evidence trail between this drug and this disease category.
Clinical Trial Evidence
Currently no related clinical trials registered for pulmonary hypertension with unclear multifactorial mechanism.
Literature Evidence
Currently no related literature available for Felodipine in pulmonary hypertension with unclear multifactorial mechanism.
All Predicted Indications — Summary
This evidence pack covers 7 TxGNN-predicted indications for Felodipine, all cardiovascular in nature and consistent with the CCB mechanism. The table below provides a comparative overview:
| Rank | Indication | TxGNN Score | Evidence Level | Trials | Publications | Decision |
|---|---|---|---|---|---|---|
| 1 | Pulmonary hypertension with unclear multifactorial mechanism | 99.91% | L5 | 0 | 0 | Hold |
| 2 | Pulmonary hypertension owing to lung disease and/or hypoxia | 99.91% | L5 | 0 | 20 (non-specific†) | Hold |
| 3 | Malignant hypertensive renal disease | 99.90% | L5 | 0 | 0 | Hold |
| 4 | Malignant renovascular hypertension | 99.90% | L5 | 0 | 1 (case report‡) | Hold |
| 5 | Braddock syndrome | 99.88% | L5 | 0 | 0 | Hold |
| 6 | Chronic pulmonary heart disease | 99.19% | L4 | 0 | 3 | Hold |
| 7 | Prinzmetal angina | 99.07% | L2 | 0 | 9 | Proceed with Guardrails |
† The 20 publications retrieved for Rank 2 are general hypoxia biology reviews (e.g., neurodegeneration, cancer, altitude physiology) — none address Felodipine in lung disease-related PH. Effective drug-specific evidence for this indication is absent.
‡ The single publication for Rank 4 (PMID 8893190) describes a post-adrenalectomy renovascular hypertension case with no relevance to Felodipine treatment.
Best-Evidenced Indication: Prinzmetal Angina (Rank 7)
Mechanistic Rationale
Prinzmetal (variant/vasospastic) angina arises from episodic coronary artery spasm causing transient transmural ischemia. The pathophysiological mechanism directly implicates smooth muscle L-type calcium channel activation. Calcium channel blockers therefore represent the Class I, first-line pharmacotherapy for this condition per ACC/AHA and ESC guidelines — their antivasospastic mechanism is the primary therapeutic basis, not a secondary or off-label extrapolation.
Felodipine, as a DHP-CCB with relatively high coronary vascular selectivity and a long-acting extended-release (ER) formulation enabling once-daily dosing, is particularly well-suited for continuous spasm suppression. Direct clinical studies confirm its efficacy specifically in Prinzmetal angina patients.
Literature Evidence for Prinzmetal Angina
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 1746458 | 1991 | Comparative RCT | Am J Cardiology | Felodipine 10–20 mg once daily vs. nifedipine 20 mg QID in 30 Prinzmetal angina patients; demonstrated comparable antiischemic efficacy with once-daily dosing advantage |
| 8013514 | 1994 | Clinical Provocation Study | European Heart Journal | Extended-release felodipine 20 mg effectively prevented ergonovine-induced myocardial ischemia at both 4 h and 24 h post-dose in 14 Prinzmetal angina patients |
| 2909138 | 1989 | Clinical Provocation Study | Am J Cardiology | Felodipine significantly reduced hyperventilation-induced ischemic attacks in variant angina; demonstrated 24-hour protective coverage |
| 7744087 | 1995 | Double-blind RCT | European Heart Journal | Felodipine ER 10 mg improved exercise duration by 66 s vs. placebo (vs. 50 s for nifedipine SR); benefits sustained to end of dosing interval (24 h) |
| 7728649 | 1995 | Focused Review | Can J Cardiology | CCBs as first-choice therapy in Prinzmetal’s angina; Felodipine specifically reviewed for its vascular selectivity and sustained 24-hour antianginal coverage |
| 14689111 | 2003 | Review | Herz | Differential CCB therapy across indications including vasospastic angina; Felodipine’s clinical profile discussed |
| 3345765 | 1988 | Case Series | European Heart Journal | Exercise-induced ST-elevation patterns in Prinzmetal’s angina; contextual clinical background |
| 19052677 | 2008 | Case Report | Can J Cardiology | Vasospasm-induced polymorphic ventricular tachycardia; CCB management context |
| 15222138 | 2004 | Case Report | Orvosi Hetilap | Nicergoline-induced Prinzmetal angina episode; CCB as rescue management |
Supporting Evidence: Chronic Pulmonary Heart Disease (Rank 6, L4)
For chronic pulmonary heart disease (cor pulmonale), two older Felodipine-specific hemodynamic studies exist and are worth noting:
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 2838319 | 1988 | Clinical Hemodynamic Study | European Respiratory Journal | Felodipine infusion (0.9 mg/h) in 11 advanced COLD patients reduced PVR by 18% and SVR by 33%, increased cardiac output by 32%, and improved biventricular ejection fraction — however, long-term outcome data are absent |
| 2487551 | 1989 | Acute Hemodynamic Study | Cardiovascular Drugs Therapy | Felodipine in 10 chronic congestive heart failure patients; acute assessment of central hemodynamics and regional blood flow distribution |
| 3154329 | 1988 | Review | Cardiovascular Drugs Therapy | CCB comparative efficacy across hypertension and minor cardiovascular indications; class-level context |
⚠️ Clinical caution: Despite these hemodynamic signals, CCBs in COPD-related pulmonary hypertension (WSPH Group 3) carry meaningful risks — particularly abolishing hypoxic pulmonary vasoconstriction (HPV) and worsening ventilation-perfusion mismatch. Current guidelines do not recommend CCBs for Group 3 PH. These older studies should not be interpreted as sufficient justification for clinical use without further investigation.
Philippines Market Information
Felodipine is not currently marketed or registered in the Philippines. No FDA-Philippines (FR number) authorizations are on record in this evidence pack. This represents a primary regulatory barrier for any local repurposing pathway.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
| **Decision: Hold (Rank 1 Indication) | Proceed with Guardrails (Prinzmetal Angina, Rank 7)** |
Rationale: The top TxGNN-ranked prediction — pulmonary hypertension with unclear multifactorial mechanism — has no clinical evidence (L5) and carries mechanistic contraindications in the relevant WSPH Group 5 context; a Hold is clearly appropriate. By contrast, Prinzmetal angina (rank 7, score 99.07%, L2) is supported by multiple direct Felodipine clinical studies, aligns with Class I guideline recommendations for CCB use in vasospastic angina, and represents a biologically coherent and clinically meaningful repurposing opportunity warranting systematic evaluation.
To advance the Prinzmetal angina repurposing pathway, the following steps are required:
- Regulatory registration: Felodipine is not registered in the Philippines — an NDA or supplemental indication filing with FDA-Philippines is a prerequisite for any local clinical or commercial pathway
- Safety documentation: Retrieve complete package insert (PI/SmPC) for warnings, contraindications, and drug interactions; this data was unavailable in the current evidence pack (blocking gap DG001)
- MOA data: Query DrugBank API (DB01023) to retrieve the full mechanism of action profile (gap DG002), supporting both regulatory submissions and risk-benefit documentation
- Guideline confirmation: Verify current ACC/AHA and ESC guideline standing for CCB use in vasospastic angina to document Class I recommendation
- Competitive landscape: Map existing CCBs registered in the Philippines (e.g., amlodipine, nifedipine) for vasospastic angina; assess whether Felodipine’s once-daily ER formulation offers meaningful clinical differentiation
- Formulation availability: Confirm the extended-release (ER) oral formulation is accessible locally, as the pivotal clinical studies used Felodipine ER
Disclaimer: This report is for research reference only and does not constitute medical advice. All repurposing candidates require clinical validation before therapeutic application.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.